Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
KPTI
#4690
Karyopharm Therapeutics Inc. - Common Stock
0.4
0
USD
-0.07%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-6.98%
Monthly Change
-74.84%
6 month change
-95.35%
Year Change
-95.85%
Previous Close
0.4
3
Open
0.4
3
Low
0.3
9
High
0.4
3
Markets
US Stock Market
Healthcare
Biotechnology
KPTI
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
4.98 M
5.28 M
7.56 M
7.67 M
8.42 M
18.34 M
22.68 M
Valuation ratios
Enterprise value
1.19 B
487.83 M
404.41 M
222.39 M
117.5 M
190.28 M
84.01 M
Price to earnings ratio
—
—
-1.61
-0.72
-0.73
-0.41
-0.04
Price to sales ratio
—
—
1.7
0.7
0.59
0
—
Price to cash flow ratio
—
—
-1.78
1.11
0.67
-0
-0
Price to book ratio
—
—
-16.02
0.76
0.46
-0
-0
Enterprise value to EBITDA ratio
-7.22
-4.96
-2.86
-1.68
-1.02
-2.2
—
Profitability ratios
Return on assets %
-0.63
-0.41
-0.46
-0.6
-0.46
-1.81
-0.6
Return on equity %
-3.88
1.56
9.92
1.05
0.41
0.67
0.2
Return on invested capital %
-2 279.29
-1 089.01
-2 195.07
-3 390.53
-2 079.79
-1 258.83
190.67
Gross margin %
99.7
100
100
100
100
104.48
100
Operating margin %
-159
-46.84
-90.53
-88.71
-82.24
-64.88
67.38
EBITDA margin %
-152.25
-46.83
-90.14
-90.59
-79.34
-61.89
—
Net margin %
-181.59
-59.14
-105.23
-97.99
-52.62
-140.22
200.48
Liquidity ratios
Quick ratio
4.55
3.68
5.25
3.32
1.64
1.08
0.76
Current ratio
4.59
3.74
5.31
3.37
1.7
1.12
0.79
Inventory turnover
0.22
0
—
—
—
—
—
Asset turnover
0.36
0.68
0.47
0.49
0.72
1.29
0.28
Solvency ratios
Debt to assets ratio
0.38
0.55
0.47
0.71
0.58
1.07
1.13
Debt to equity ratio
2.33
-2.12
-10.21
-1.25
-0.51
-0.4
0.38
Long term debt to total assets ratio
0.38
0.55
0.47
0.71
0.58
1.07
1.13
Long term debt to total equity ratio
2.33
-2.12
-10.21
-1.25
-0.51
-0.4
0.38
Per share metrics
Operating cash flow per share
—
—
-27.4
-12.18
-15.08 K
-6 892.46
-3 538.77
EBIT per share
—
—
-26.05
-17.01
-14.13 K
-8 867.4
-4 750.76
EBITDA per share
—
—
-25.94
-17.37
-13.63 K
-7 913.4
—
Total debt per share
—
—
31.17
22.45
11.19 K
10.59 K
4.92
Cash per share
—
—
50.93
25.14
12.86 K
5 825.33
2 249.64
Net current asset value per share
—
—
64.15
30.72
18.51 K
9 432.65
3 676.07
Tangible book value per share
—
—
-3.05
-17.89
-22 K
-26.79 K
-11.41 K
Working capital per share
—
—
52.08
21.6
7 597.41
1 013.81
-962.58
Book value per share
—
—
-3.05
-17.89
-22 K
-26.79 K
-11.41 K
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Karyopharm Therapeutics Extends Forbearance Period To October 15
12 Health Care Stocks Moving In Monday's Intraday Session
Geron Corp. Stock: Management's Plan Taking Shape (NASDAQ:GERN)
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
Karyopharm: "Hold" Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI)
Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead (NASDAQ:KPTI)
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up (GERN)
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell